NVCT vs. ERAS, KRRO, LRMR, FULC, VERV, NGNE, MREO, SLRN, TBPH, and CTNM
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Erasca (ERAS), Korro Bio (KRRO), Larimar Therapeutics (LRMR), Fulcrum Therapeutics (FULC), Verve Therapeutics (VERV), Neurogene (NGNE), Mereo BioPharma Group (MREO), Acelyrin (SLRN), Theravance Biopharma (TBPH), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
Nuvectis Pharma (NASDAQ:NVCT) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Nuvectis Pharma is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 38.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 21.5% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Nuvectis Pharma presently has a consensus price target of $21.00, suggesting a potential upside of 210.19%. Erasca has a consensus price target of $6.83, suggesting a potential upside of 171.16%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Erasca.
In the previous week, Erasca had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Erasca and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.63 beat Erasca's score of 0.23 indicating that Nuvectis Pharma is being referred to more favorably in the media.
Erasca's return on equity of -38.83% beat Nuvectis Pharma's return on equity.
Erasca received 10 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 88.89% of users gave Nuvectis Pharma an outperform vote while only 64.29% of users gave Erasca an outperform vote.
Nuvectis Pharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Summary
Erasca beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
